{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"28.4","value":"2.4"},{"groupId":"OG001","lowerLimit":"6.2","upperLimit":"16.5","value":"13.3"},{"comment":"Chronic Lymphocytic Leukemia group had no progression events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"description":"Duration of response was the time from date of response to date of progression and evaluated among participants with response. According to the 1999 international response criteria as published by Cheson, progression/progressive disease is defined as \\>=50% increase from nadir in the sum of the products of the greatest diameters of any previously identified abnormal node for PRs or nonresponders, or appearance of any new lesion during or at the end of therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received Temsirolimus (CCI-779) IV over 30 minutes on days 1,8,15, and 22. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients were followed every 8 weeks. Aggressive B-cell lymphoma group was defined as patients with histologic subtypes included diffuse large B-cell lymphoma and transformed follicular lymphoma.","id":"OG000","title":"Aggressive B-cell Lymphoma"},{"description":"Patients received Temsirolimus (CCI-779) IV over 30 minutes on days 1,8,15, and 22. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients were followed every 8 weeks. Follicular lymphoma group was defined as patients with histologic subtypes included follicular lymphoma.","id":"OG001","title":"Follicular Lymphoma"},{"description":"Patients received Temsirolimus (CCI-779) IV over 30 minutes on days 1,8,15, and 22. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients were followed every 8 weeks. Chronic lymphocytic leukemia group was defined as patients with histologic subtypes included chronic lymphocytic leukemia, small lymphocytic lymphoma, and other indolent lymphomas.","id":"OG002","title":"Chronic Lymphocytic Leukemia"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 6 years","title":"Duration of Response","type":"PRIMARY","unitOfMeasure":"Month"}